New York, May 28, 2026, 08:01 EDT
Jade Biosciences (NASDAQ) is set to open Thursday in the U.S. after announcing it started dosing patients in two clinical trials. The company said it began a Phase 2 study in kidney disease and a first-in-human study in rheumatoid arthritis. Shares last changed hands at $21.50, off 21 cents from the previous close, in premarket activity.
That’s important as Jade shifts from early promise to actual patient data. A Phase 2 study gives an early look at whether a drug helps patients, while Phase 1 is just the initial test in people, mainly covering safety, drug exposure, and first biological effects.
Jade Biosciences said its Phase 2 JUNIPER trial is looking at JADE101 in patients with immunoglobulin A nephropathy, or IgAN, a chronic autoimmune kidney disorder. Interim data are expected in 2027. The trial will monitor proteinuria, or excess protein in urine, as a sign of kidney damage.
Andrew King, Jade’s president of research and development, said JADE101 could “drive deep and sustained IgA reductions” and allow for subcutaneous dosing as infrequently as every eight weeks. JADE101 targets APRIL, a protein tied to antibody production and now a key focus in IgAN drug research. Jade Biosciences
Jade dosed the first patient in its Phase 1 trial of JADE201 for rheumatoid arthritis. The drug goes after BAFF-R, found on B cells, which can be involved in autoimmune disease. Jade said the study will use a single ascending dose to check safety, tolerability, drug levels and biological effects.
King said JADE201 aims for “deeper, more durable B cell depletion” with less frequent under-the-skin shots. Interim first-in-human data for JADE201 are due in 2027, so next year will be the main readout window for both programs. Jade Biosciences
Stocks closed at new highs on Wednesday, with the S&P 500, Dow and Nasdaq each hitting records, according to AP market data. The Nasdaq edged up 0.1%. The overall tape was stronger than Jade’s last close.
Jade this month told investors it’s moving into a “new phase of focused clinical execution.” The company had $311.3 million in cash, cash equivalents and investments at March 31, which it says will cover operations through the first half of 2028. Jade Biosciences
The competitive bar is moving higher. The FDA gave accelerated approval to Otsuka’s Voyxact for adults with primary IgAN at risk of progression in November 2025. Vertex also has plans to file for U.S. approval for povetacicept, its own late-stage IgAN drug.
Still, the risks here are clear. Jade’s latest milestones just start new trials—they aren’t evidence the drugs work yet. Filings note that studies could get pushed back, safety issues could show up, and these drugs might not get approved. With interim data still ahead, the stock faces risk from any funding crunch or a change in how much appetite investors have for early-stage biotech.
Jade filed with the SEC on May 7 to register as much as $600 million in securities, and set up an at-the-market offering for up to $200 million in stock through Jefferies. The at-the-market plan allows the company to sell shares into the market over time, which can boost cash but also dilute shareholders.
Right now, there are two clear milestones on the calendar for the market. After that, there’s a long wait for more solid clinical results. That kind of setup can keep a biotech name trading, but it won’t close out the bigger story.
